PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32830548-11 2020 We conclude that in PCOS, salsalate-induced suppression of OS and inflammation ameliorates ovarian androgen hypersecretion and may induce ovulation while maintaining insulin action. salicylsalicylic acid 26-35 insulin Homo sapiens 166-173 25683256-1 2015 To elucidate whether increased insulin concentration after salsalate treatment (3 g/day for 7 days) is attributable to an increased insulin secretion rate (ISR) or to reduced metabolic clearance of endogenous insulin (MCI) during stepped glucose infusion (SGI). salicylsalicylic acid 59-68 insulin Homo sapiens 31-38 31440379-4 2019 SAL lowered levels of glucagon and raised levels of insulin in plasma, while improving both insulin sensitivity and beta-cell function. salicylsalicylic acid 0-3 insulin Homo sapiens 52-59 31440379-4 2019 SAL lowered levels of glucagon and raised levels of insulin in plasma, while improving both insulin sensitivity and beta-cell function. salicylsalicylic acid 0-3 insulin Homo sapiens 92-99 31440379-5 2019 The protective effect of SAL is likely due to diminished beta-cell dedifferentiation, manifested as relative declines in Neurogenin 3+/insulin- cells and synaptophysin+/islet hormone- cells and increased expression of beta-cell-specific transcription factor Foxo1. salicylsalicylic acid 25-28 insulin Homo sapiens 135-142 26350812-0 2015 Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals. salicylsalicylic acid 0-9 insulin Homo sapiens 103-110 26350812-1 2015 BACKGROUND AND OBJECTIVE: Although salsalate administration consistently lowers plasma triglyceride concentrations in patients with type II diabetes, prediabetes, and/or insulin resistance, changes in low-density lipoprotein cholesterol (LDL-C) concentrations have been inconsistent; varying from no change to a significant increase. salicylsalicylic acid 35-44 insulin Homo sapiens 170-177 26350812-9 2015 CONCLUSIONS: Atherogenicity of the lipid, lipoprotein, and apoprotein profile of insulin-resistant individuals who were overweight or obese improved significantly in association with salsalate treatment. salicylsalicylic acid 183-192 insulin Homo sapiens 81-88 25683256-6 2015 Salsalate did not alter insulin secretion, but lowered MCI, indicating that a reduction in insulin clearance is the principal mechanism for increased insulin levels after salsalate administration. salicylsalicylic acid 0-9 insulin Homo sapiens 91-98 25683256-6 2015 Salsalate did not alter insulin secretion, but lowered MCI, indicating that a reduction in insulin clearance is the principal mechanism for increased insulin levels after salsalate administration. salicylsalicylic acid 0-9 insulin Homo sapiens 91-98 25683256-6 2015 Salsalate did not alter insulin secretion, but lowered MCI, indicating that a reduction in insulin clearance is the principal mechanism for increased insulin levels after salsalate administration. salicylsalicylic acid 171-180 insulin Homo sapiens 91-98 25683256-6 2015 Salsalate did not alter insulin secretion, but lowered MCI, indicating that a reduction in insulin clearance is the principal mechanism for increased insulin levels after salsalate administration. salicylsalicylic acid 171-180 insulin Homo sapiens 91-98 24963111-2 2014 The aim of this study was to evaluate the effect of salsalate treatment on insulin action, secretion, and clearance rate in nondiabetic individuals with insulin resistance. salicylsalicylic acid 52-61 insulin Homo sapiens 75-82 25644856-6 2015 Salsalate increased insulin AUC by 38% (P = 0.01) and HOMA-B by 47.2% (P < 0.01) while estimates of insulin sensitivity/resistance were unaffected. salicylsalicylic acid 0-9 insulin Homo sapiens 20-27 25317247-6 2014 Interleukin 1 and tumor necrosis factor-alpha antagonists are in trials and NSAIDs such as salsalate have shown an improvement in insulin sensitivity. salicylsalicylic acid 91-100 insulin Homo sapiens 130-137 24963111-0 2014 Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. salicylsalicylic acid 10-19 insulin Homo sapiens 23-30 24963111-2 2014 The aim of this study was to evaluate the effect of salsalate treatment on insulin action, secretion, and clearance rate in nondiabetic individuals with insulin resistance. salicylsalicylic acid 52-61 insulin Homo sapiens 153-160 24963111-3 2014 RESEARCH DESIGN AND METHODS: This was a randomized (2:1), single-blind, placebo-controlled study of salsalate (3.5 g daily for 4 weeks) in nondiabetic individuals with insulin resistance. salicylsalicylic acid 100-109 insulin Homo sapiens 168-175 24963111-11 2014 CONCLUSIONS: Salsalate treatment in nondiabetic, insulin-resistant individuals improved fasting, but not postprandial, glucose and triglyceride concentration. salicylsalicylic acid 13-22 insulin Homo sapiens 49-56 21938543-8 2013 Fasting insulin levels were increased in the salsalate group from 18.8 +- 1.6 to 21.6 +- 3.9, while they decreased in the placebo group. salicylsalicylic acid 45-54 insulin Homo sapiens 8-15 25126374-6 2014 Salsalate belongs to the salicylate drug class, which has been shown to inhibit I-kappaB kinase, thereby inhibiting the nuclear factor-kappaB (NF-kappaB) cascade and decreasing the production of inflammatory cytokines, as well as decreasing insulin resistance. salicylsalicylic acid 0-9 insulin Homo sapiens 241-248 25126374-10 2014 CONCLUSION: As shown in this review, salsalate therapy at the dose of 3 g to 4.5 g daily can lower insulin resistance and reduce the levels of glucose, triglycerides, and free fatty acid concentrations with minimal side effects. salicylsalicylic acid 37-46 insulin Homo sapiens 99-106 21617098-0 2011 Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. salicylsalicylic acid 0-9 insulin Homo sapiens 73-80 23801715-6 2013 The salicylate prodrug salsalate has been shown to improve metabolic parameters in subjects with insulin resistance and prediabetes, and whether this might be mediated in part by AMPK is discussed. salicylsalicylic acid 23-32 insulin Homo sapiens 97-104 23825542-9 2013 Both salsalate and salicylate treatment significantly improved glucose intolerance and insulin sensitivity, accompanied by reduced SeP mRNA and protein expression in HFD-fed rats and db/db mice, respectively. salicylsalicylic acid 5-14 insulin Homo sapiens 87-94 23370525-3 2013 This trial aimed to evaluate the effect of salsalate vs placebo on insulin resistance and glycaemia in impaired fasting glucose and/or impaired glucose tolerance. salicylsalicylic acid 43-52 insulin Homo sapiens 67-74 23370525-12 2013 Insulin clearance was reduced with salsalate. salicylsalicylic acid 35-44 insulin Homo sapiens 0-7 22784842-9 2012 CONCLUSION: Treatment with salsalate can reduce insulin resistance and the FPG level in subjects with prediabetes. salicylsalicylic acid 27-36 insulin Homo sapiens 48-55 22784842-1 2012 OBJECTIVE: To evaluate the effect of salsalate as an antiinflammatory agent on insulin resistance and glycemic control in persons with prediabetes. salicylsalicylic acid 37-46 insulin Homo sapiens 79-86 21617098-14 2011 CONCLUSIONS: High plasma concentrations of FFAs cause both microvascular and metabolic insulin resistance, which can be prevented or attenuated by salsalate treatment. salicylsalicylic acid 147-156 insulin Homo sapiens 87-94 17959861-5 2008 Although insulin levels were unchanged, fasting and oral glucose tolerance test C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P < 0.03), consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin clearance. salicylsalicylic acid 114-123 insulin Homo sapiens 203-210 21289240-0 2011 Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions. salicylsalicylic acid 54-63 insulin Homo sapiens 172-179 21289240-8 2011 However, salsalate repressed lipid-induced reduction in CHOox and reduced insulin clearance, resulting in higher insulin levels under basal as well as under clamp conditions (~25 and ~39%, respectively). salicylsalicylic acid 9-18 insulin Homo sapiens 74-81 21289240-8 2011 However, salsalate repressed lipid-induced reduction in CHOox and reduced insulin clearance, resulting in higher insulin levels under basal as well as under clamp conditions (~25 and ~39%, respectively). salicylsalicylic acid 9-18 insulin Homo sapiens 113-120 21289240-11 2011 CONCLUSION: We conclude that salsalate failed to improve whole-body insulin sensitivity but increased basal fat oxidation and insulin-stimulated CHOox, indicating improved metabolic flexibility. salicylsalicylic acid 29-38 insulin Homo sapiens 126-133 19104769-0 2009 The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. salicylsalicylic acid 14-23 insulin Homo sapiens 27-34 19104769-2 2009 The present study evaluated whether treatment with salsalate, a traditional anti-inflammatory medication, would improve insulin action in obese non-diabetic individuals. salicylsalicylic acid 51-60 insulin Homo sapiens 120-127 19104769-10 2009 The effect of salsalate on R (d) disappeared (p = 0.9) after normalising to increased insulin concentrations (701 [285] vs 535 [201] pmol/l, p < 0.0001) measured during the clamp. salicylsalicylic acid 14-23 insulin Homo sapiens 86-93 19337387-0 2008 Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. salicylsalicylic acid 7-16 insulin Homo sapiens 60-67 17959861-5 2008 Although insulin levels were unchanged, fasting and oral glucose tolerance test C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P < 0.03), consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin clearance. salicylsalicylic acid 114-123 insulin Homo sapiens 203-210